Press Releases

AbCellera, a technology company with a centralized operating system for next-generation antibody discovery, today announced it has acquired TetraGenetics, Inc. (TetraGenetics), a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins, in an all-cash transaction that includes an upfront payment, the potential for payments based on the achievement of technical milestones, and additional development and commercial mileston

UroGen Pharma Ltd. a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on-demand via the conference portal and through the Investors section of UroGen’s website, www.urogen.com, beginning at 7:00 a.m. Eastern Time on Monday, September 13, 2021. A replay of the webcast

BeiGene, Ltd. a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its anti-PD-1 antibody tislelizumab as a treatment for patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic

Kintor Pharmaceutical Limited , a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the primary endpoint of phase II clinical trial of  pyrilutamide ("KX-826", tincture) in China for the treatment of androgenetic alopecia (AGA) was met, which was statistically significant and clinically meaningful. The phase II clinical trial was a multicenter, randomized, double-blinded, placebo-controlled study to

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced that they have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa, AM-Pharma’s proprietary recombinant human alkaline phosphata

Health industry digitalization is one of the highest priorities in the healthcare sector these days. In perspective, it improves current living standards with quicker and easier access to help. The Healthcare Automation and Digitalization Congress business program will cover digital trends in the healthcare industry. The Congress will take place on BGS Online Platform on the 27th - 28th of September, 2021. Growth of pharmaceutical costs, poorly integrated doctor-patient interaction,

In order to meet the rapidly growing global demand for gene, cell and RNA therapies, Flash Therapeutics, a CDMO with strong technological expertise, is accelerating the ramp-up of its biomanufacturing capabilities. This will allow it to position itself for the production of large-scale clinical batches, including both integrative DNA and RNA technologies (proprietary LentiFlash® technology). This ambition requires an overall investment of around €15M to ensure the growth of

NTx, a biomanufacturing and bioinformatics company, today announced a collaboration with the University of Notre Dame Department of Computer Science and Engineering. Together, they are working to identify and evaluate the drug potential of previously not described natural products with a jointly developed algorithm called DruID With the advent of quick and inexpensive next-generation DNA sequencing technologies, bioinformatic tools can tap into natural products, the main source for

Active Implants LLC, a company that develops orthopedic implant solutions, today announced that it has reached an exclusive agreement with Geistlich Pharma AG to be the exclusive Swiss distributor of the company’s NUsurface® Meniscus Prothesis. The world’s first “artificial meniscus” is now available in Belgium, Germany, Israel, Italy, Switzerland and the UK. The relationship between Active Implants and Geistlich Pharma began in 2019 with the launch of th

Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc.  announces today that the clinical trial application of ASC42 to treat patients with primary biliary cholangitis (PBC) has been accepted for review by China National Medical Products Administration (NMPA). ASC42 is an in-house developed, novel non-steroidal, selective, potent FXR agonist with best-in-class potential. On June 16, 2021, Gannex announced positive topline results of safety and pharmacodynamic b